Reserve Shares Today!

Be part of the relief for OA

Cytonics has received over $15M in funding to-date, including $1.8M in grants from the National Institute of Health and a $4M investment from Synthes (a Johnson and Johnson company). We are seeking to raise $19M by conducting a public offering under Regulation A. Proceeds will be used to advance our lead drug candidate, Cyt-108, into FDA clinical trials and fund ongoing business operations.

Cytonics Corporation is offering securities under Regulation A through SI Securities, LLC (“SI Securities”). The Company has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained at: